Literature DB >> 7251048

Classes and subclasses of rat antibodies: reaction with the antigen and interaction of the complex with the complement system.

G A Medgyesi, K Miklós, J Kulics, G Füst, J Gergely, H Bazin.   

Abstract

Antibodies against the dinitroaminophenyl (DNAP) haptenic group were raised in outbred CFY rats using HSA or LPS as carrier. Antibodies isolated by immunoadsorbent techniques were resolved into fractions representing distinct isotypes, and the resulting fractions were tested for avidity. Subclass IgG2a was found to contain antibodies of an avidity index lower than those of other IgG subclasses or IgM. IgG2a was the only isotype detected when DNAP-LPS was used for immunization. Complexes containing defined isotypes were compared for their capacity to activate homologous complement. IgGl type antibody-containing complexes displayed a low complement activating capacity compared with those containing IgG2b, IgG2c or IgG2a. The latter subclass when complexed with antigen can thus induce complement-dependent processes in spite of a low avidity. Insoluble complexes of IgG antibodies were rapidly solubilized in rat serum (CRA phenomenon), except those containing predominantly IgG2c.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7251048      PMCID: PMC1555175     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  11 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

2.  Effects of C-1 on the size of soluble immune aggregates and on their processing by macrophages.

Authors:  A Kijlstra; L A van Es; M R Daha
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

3.  The fixation of complement and the activated first component (C1) of complement by complexes formed between antibody and divalent hapten.

Authors:  N E Hyslop; R R Dourmashkin; N M Green; R R Porter
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

4.  Determination of avidity of anti-albumin antibodies in the mouse. Influence of the number of cells transferred on the quality of the secondary adoptive response.

Authors:  F Celada; D Schmidt; R Strom
Journal:  Immunology       Date:  1969-08       Impact factor: 7.397

5.  The effect of immune complex composition on complement activation and complement dependent complex release.

Authors:  E Rajnavölgyi; G Füst; J Kulics; J Ember; G A Medgyesi; J Gergely
Journal:  Immunochemistry       Date:  1978-12

Review 6.  Mechanism of solubilization of immune aggregates by complement. Implications for immunopathology.

Authors:  M Takahashi; J Czop; A Ferreira; V Nussenzweig
Journal:  Transplant Rev       Date:  1976

7.  Activation of the classical complement pathway by homogeneous anti-SIII antibody bound to bivalent or trivalent oligosaccharide antigens.

Authors:  G A Medgyesi; G Füst; J Gergely; J C Jaton
Journal:  Mol Immunol       Date:  1979-11       Impact factor: 4.407

8.  Classes and subclasses of rat immunoglobulins: interaction with the complement system and with staphylococcal protein A.

Authors:  G A Medgyesi; G Füst; J Gergely; H Bazin
Journal:  Immunochemistry       Date:  1978-02

9.  Interactions between mouse immunoglobulins and staphylococcal protein A.

Authors:  M P Chalon; R W Milne; J P Vaerman
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

10.  Generation of memory cells. III. Antibody class requirements for the generation of B-memory cells by antigen--antibody complexes.

Authors:  G G Klaus
Journal:  Immunology       Date:  1979-06       Impact factor: 7.397

View more
  14 in total

1.  The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.

Authors:  Y M Lucisano Valim; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

2.  Bidirectional effect of met-enkephalin on macrophage effector functions.

Authors:  G Fóris; G A Medgyesi; M Hauck
Journal:  Mol Cell Biochem       Date:  1986-02       Impact factor: 3.396

3.  Immunoselection of tumor variants resistant to antibody-mediated cytotoxicity. Their immunologic and metastatic characterization.

Authors:  J R Starkey; W C Davis; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Immunologic enhancement of experimental metastasis in the rat.

Authors:  J R Starkey; S S Ristow; T L McDonald; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Immunogenicity of antigen complexed with antibody. I. Role of different isotypes.

Authors:  A I Farkas; G A Medgyesi; G Füst; K Miklós; J Gergely
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

6.  Characterization of different types of experimental autoimmune thyroiditis in the Buffalo strain rat.

Authors:  S B Cohen; A P Weetman
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

7.  Effects of urethan on lymphokine-producing activity of lymphocytes and on some functions of peritoneal macrophages in rats.

Authors:  G Fóris; F Boján; G A Medgyesi; T Szilágyi
Journal:  Agents Actions       Date:  1983-02

8.  Effect of angiotensin II on macrophage functions.

Authors:  G Fóris; B Dezsö; G A Medgyesi; G Füst
Journal:  Immunology       Date:  1983-03       Impact factor: 7.397

9.  Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis.

Authors:  Jie Luo; Jon Lindstrom
Journal:  J Immunol       Date:  2014-10-06       Impact factor: 5.422

10.  Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models.

Authors:  Roberto Di Niro; Federica Ziller; Fiorella Florian; Sergio Crovella; Marco Stebel; Marco Bestagno; Oscar Burrone; Andrew R M Bradbury; Paola Secco; Roberto Marzari; Daniele Sblattero
Journal:  BMC Biotechnol       Date:  2007-08-01       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.